| Year |
Citation |
Score |
| 2022 |
Ahmad K, Khangoora V, Nathan SD. Lung Disease-Related Pulmonary Hypertension. Cardiology Clinics. 40: 77-88. PMID 34809919 DOI: 10.1016/j.ccl.2021.08.005 |
0.36 |
|
| 2021 |
Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. The Lancet. Respiratory Medicine. PMID 34214475 DOI: 10.1016/S2213-2600(21)00165-X |
0.303 |
|
| 2021 |
Behr J, Nathan SD. Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. Current Opinion in Pulmonary Medicine. PMID 34127619 DOI: 10.1097/MCP.0000000000000790 |
0.314 |
|
| 2021 |
DuBrock HM, Nathan SD, Reeve BB, Kolaitis NA, Mathai SC, Classi PM, Nelsen AC, Olayinka-Amao B, Norcross LN, Martin SA. Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life. Pulmonary Circulation. 11: 20458940211005641. PMID 33868642 DOI: 10.1177/20458940211005641 |
0.33 |
|
| 2021 |
Nathan SD, Barnett SD, King CS, Provencher S, Barbera JA, Pastre J, Shlobin OA, Seeger W. Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. Pulmonary Circulation. 11: 2045894021999960. PMID 33868639 DOI: 10.1177/2045894021999960 |
0.346 |
|
| 2021 |
Nathan SD, Cottin V, Behr J, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse UG, Scholle FD, et al. Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. PMID 33744088 DOI: 10.1016/j.healun.2021.02.006 |
0.349 |
|
| 2021 |
Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, ... Nathan SD, et al. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. The New England Journal of Medicine. PMID 33440084 DOI: 10.1056/NEJMoa2008470 |
0.335 |
|
| 2021 |
WAXMAN A, NATHAN S, FISHER M, JAMES FORD H, GAGERMEIER J, PARAMBIL J, RAINA A, ZWICKE D, GERKE A, SHEN E, LEE D, RAO Y, TAPSON V. DOSE RESPONSE ANALYSIS OF INHALED TREPROSTINIL IN PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND ITS EFFECTS ON CLINICAL WORSENING Chest. 160: A2279-A2280. DOI: 10.1016/j.chest.2021.07.1995 |
0.305 |
|
| 2021 |
NATHAN S, TAPSON V, RAMANI G, MEDAROV B, LEVINE D, BURGER C, EL-KERSH K, SHEN E, RAO Y, SMITH P, WAXMAN A. COMPARISON OF EFFECTS OF INHALED TREPROSTINIL ON LUNG FUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION Chest. 160: A2244-A2246. DOI: 10.1016/j.chest.2021.07.1976 |
0.346 |
|
| 2021 |
RAHAGHI F, KOLAITIS N, ADEGUNSOYE A, ALBERTO DE ANDRADE J, FLAHERTY K, LANCASTER L, LEE J, LEVINE D, PRESTON I, SAFDAR Z, SAGGAR R, SAHAY S, BETH SCHOLAND M, SHLOBIN O, ZISMAN D, ... NATHAN S, et al. SCREENING FOR PULMONARY HYPERTENSION IN PATIENTS WITH INTERSTITIAL LUNG DISEASE: RECOMMENDATIONS FROM A DELPHI CONSENSUS PANEL Chest. 160: A1239-A1242. DOI: 10.1016/j.chest.2021.07.1139 |
0.318 |
|
| 2020 |
King C, Freiheit E, Brown AW, Shlobin OA, Aryal S, Ahmad K, Khangoora V, Flaherty KR, Venuto D, Nathan SD. Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry. Chest. PMID 33075376 DOI: 10.1016/j.chest.2020.10.019 |
0.309 |
|
| 2020 |
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, et al. The Pulmonary Fibrosis Foundation Patient Registry: Rationale, Design, and Methods. Annals of the American Thoracic Society. PMID 32776789 DOI: 10.1513/AnnalsATS.202001-035SD |
0.313 |
|
| 2020 |
Collins A, King C, Shlobin O, Nathan S. OUTCOMES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS AND PULMONARY HYPERTENSION Chest. 158: A1071-A1072. DOI: 10.1016/j.chest.2020.08.988 |
0.306 |
|
| 2020 |
Rowe A, Ratwani A, Barnett S, King C, Shlobin O, Nathan S. A RETROSPECTIVE DESCRIPTIVE ANALYSIS OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE AND PULMONARY HYPERTENSION Chest. 158: A1878-A1879. DOI: 10.1016/j.chest.2020.08.1629 |
0.305 |
|
| 2019 |
Nathan SD. Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis: Echoes of the Past, Lessons for the Future. American Journal of Respiratory and Critical Care Medicine. PMID 31425662 DOI: 10.1164/rccm.201908-1510ED |
0.311 |
|
| 2019 |
Aryal S, Nathan SD. Contemporary optimized practice in the management of pulmonary sarcoidosis. Therapeutic Advances in Respiratory Disease. 13: 1753466619868935. PMID 31409257 DOI: 10.1177/1753466619868935 |
0.307 |
|
| 2019 |
King CS, Nathan SD. Pulmonary hypertension due to interstitial lung disease. Current Opinion in Pulmonary Medicine. PMID 31219836 DOI: 10.1097/MCP.0000000000000599 |
0.354 |
|
| 2018 |
El-Chemaly S, O'Brien KJ, Nathan SD, Weinhouse GL, Goldberg HJ, Connors JM, Cui Y, Astor TL, Camp PC, Rosas IO, Lemma M, Speransky V, Merideth MA, Gahl WA, Gochuico BR. Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. Plos One. 13: e0194193. PMID 29547626 DOI: 10.1371/journal.pone.0194193 |
0.336 |
|
| 2018 |
AHMAD K, SHLOBIN O, NATHAN S, KING C, ARYAL S, BROWN AW. RISING INCIDENCE OF PULMONARY EMBOLISM POST-LUNG TRANSPLANTATION: A SINGLE CENTER EXPERIENCE Chest. 154: 1103A-1104A. DOI: 10.1016/J.CHEST.2018.08.1003 |
0.31 |
|
| 2016 |
King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. The Lancet. Respiratory Medicine. PMID 27599614 DOI: 10.1016/S2213-2600(16)30222-3 |
0.306 |
|
| 2015 |
Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: A review. Respirology (Carlton, Vic.). PMID 26635297 DOI: 10.1111/resp.12691 |
0.31 |
|
| 2015 |
Baughman RP, Engel PJ, Nathan S. Pulmonary Hypertension in Sarcoidosis. Clinics in Chest Medicine. 36: 703-14. PMID 26593143 DOI: 10.1016/j.ccm.2015.08.011 |
0.305 |
|
| 2015 |
Kim SY, Diggans J, Pankratz D, Huang J, Pagan M, Sindy N, Tom E, Anderson J, Choi Y, Lynch DA, Steele MP, Flaherty KR, Brown KK, Farah H, Bukstein MJ, ... ... Nathan SD, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. The Lancet. Respiratory Medicine. 3: 473-82. PMID 26003389 DOI: 10.1016/S2213-2600(15)00140-X |
0.336 |
|
| 2015 |
Noble P, Bradford W, Costabel U, Glaspole I, Glassberg M, Gorina E, Kardatzke D, Lancaster L, Lederer D, Nathan S, Pereira C, Spirig D, Swigris J, Valeyre D, Albera C. P14 Pirfenidone is efficacious in patients with idiopathic pulmonary fibrosis (IPF) with more preserved lung function Thorax. 70: A81.1-A81. DOI: 10.1136/thoraxjnl-2015-207770.151 |
0.318 |
|
| 2014 |
Shin S, King CS, Brown AW, Albano MC, Atkins M, Sheridan MJ, Ahmad S, Newton KM, Weir N, Shlobin OA, Nathan SD. Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. Respiratory Medicine. 108: 1626-32. PMID 25225149 DOI: 10.1016/J.Rmed.2014.08.009 |
0.301 |
|
| 2014 |
Nathan SD, Carbone RG. Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trial. American Journal of Respiratory and Critical Care Medicine. 190: 131-2. PMID 25025352 DOI: 10.1164/rccm.201406-1094ED |
0.319 |
|
| 2013 |
Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clinics in Chest Medicine. 34: 695-705. PMID 24267299 DOI: 10.1016/j.ccm.2013.08.004 |
0.336 |
|
| 2013 |
King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Current Opinion in Pulmonary Medicine. 19: 466-73. PMID 23912191 DOI: 10.1097/MCP.0b013e328363f460 |
0.341 |
|
| 2013 |
Walter R, Holley A, Nathan S. Predictive Value of Lung Physiology in Idiopathic Pulmonary Fibrosis Chest. 144: 473A. DOI: 10.1378/CHEST.1704174 |
0.302 |
|
| 2012 |
Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. The European Respiratory Journal. 39: 1520-33. PMID 22241743 DOI: 10.1183/09031936.00175511 |
0.345 |
|
| 2011 |
Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, Sheridan MJ, du Bois RM. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 140: 221-229. PMID 21729893 DOI: 10.1378/chest.10-2572 |
0.345 |
|
| 2011 |
Ahmad S, Shlobin OA, Nathan SD. Pulmonary complications of lung transplantation. Chest. 139: 402-411. PMID 21285054 DOI: 10.1378/chest.10-1048 |
0.329 |
|
| 2010 |
Nathan SD, Shlobin OA, Ahmad S, Burton NA, Barnett SD, Edwards E. Comparison of wait times and mortality for idiopathic pulmonary fibrosis patients listed for single or bilateral lung transplantation. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 29: 1165-71. PMID 20598580 DOI: 10.1016/j.healun.2010.05.014 |
0.334 |
|
| 2010 |
Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respiratory Medicine. 104: 1877-1882. PMID 20547449 DOI: 10.1016/J.Rmed.2010.05.009 |
0.303 |
|
| 2010 |
Chhina M, Shlobin OA, Grant G, Nathan SD. Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis. Expert Review of Respiratory Medicine. 2: 419-31. PMID 20477206 DOI: 10.1586/17476348.2.4.419 |
0.341 |
|
| 2010 |
Minai OA, Nathan SD, Hill NS, Badesch DB, Stoller JK. Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. Respiratory Medicine. 104: 741-8. PMID 20092992 DOI: 10.1016/j.rmed.2009.12.015 |
0.315 |
|
| 2009 |
Hill N, Minai OA, Nathan S. PH in Patients with Lung Disease and Hypoxia Advances in Pulmonary Hypertension. 8: 163-171. DOI: 10.21693/1933-088X-8.3.163 |
0.32 |
|
| 2009 |
Nations JA, Nathan SD. Pulmonary Hypertension in Interstitial Lung Disease Diagnosis and Management Clinical Pulmonary Medicine. 16: 252-257. DOI: 10.1097/CPM.0B013E3181B56AC0 |
0.307 |
|
| 2008 |
Nathan SD. Pulmonary hypertension in interstitial lung disease. International Journal of Clinical Practice. Supplement. 21-8. PMID 18720579 DOI: 10.1111/j.1742-1241.2008.01624.x |
0.312 |
|
| 2008 |
Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, Ahmad S, Saggar R, Libre E, Lynch JP, Zisman DA. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine. 102: 1305-10. PMID 18619825 DOI: 10.1016/j.rmed.2008.03.022 |
0.302 |
|
| 2008 |
Nathan SD, Shlobin OA, Ahmad S, Barnett SD, Burton NA, Gladwin MT, Machado RF. Pulmonary hypertension in patients with bronchiolitis obliterans syndrome listed for retransplantation. American Journal of Transplantation. 8: 1506-1511. PMID 18510629 DOI: 10.1111/J.1600-6143.2008.02277.X |
0.318 |
|
| 2008 |
Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, Burton N, Leslie K. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration; International Review of Thoracic Diseases. 76: 288-94. PMID 18216461 DOI: 10.1159/000114246 |
0.319 |
|
| 2008 |
Zisman DA, Karlamangla AS, Kawut SM, Shlobin OA, Saggar R, Ross DJ, Schwarz MI, Belperio JA, Ardehali A, Lynch JP, Nathan SD. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest. 133: 640-5. PMID 18198245 DOI: 10.1378/chest.07-2488 |
0.311 |
|
| 2008 |
Minai OA, Nathan SD, Hill NS, Badesch DB, Stoller JK. PRACTICE PATTERNS REGARDING MANAGING PULMONARY HYPERTENSION IN PATIENTS WITH PARENCHYMAL LUNG DISEASES: RESULTS OF AN ACCP SURVEY Chest. 134: 134P. DOI: 10.1378/CHEST.134.4_MEETINGABSTRACTS.P134002 |
0.304 |
|
| 2007 |
Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. The European Respiratory Journal. 30: 715-21. PMID 17626111 DOI: 10.1183/09031936.00107206 |
0.313 |
|
| 2007 |
Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest. 131: 657-663. PMID 17356077 DOI: 10.1378/chest.06-2485 |
0.306 |
|
| 2007 |
Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. American Journal of Respiratory and Critical Care Medicine. 175: 875-80. PMID 17255562 DOI: 10.1164/Rccm.200608-1153Cc |
0.308 |
|
| 2007 |
Cuttica MJ, Anderson K, Barnett CF, Shlobin OA, Ahmad S, Barnett S, Machado R, Gladwin M, Nathan SD. Prevalence And Impact Of Pulmonary Hypertension In Patients With Chronic Obstructive Pulmonary Disease (Copd) Listed For Lung Transplantation Chest. 132: 621. DOI: 10.1378/Chest.132.4_Meetingabstracts.621A |
0.353 |
|
| 2007 |
Nathan SD, Anderson K, Barnett SD, Ahmad S, Shlobin OA, Machado R, Burton N, Gladwin M. PULMONARY HYPERTENSION IN PATIENTS WITH BRONCHIOLITIS OBLITERANS POST-LUNG TRANSPLANTATION Chest. 132: 596B. DOI: 10.1378/CHEST.132.4_MEETINGABSTRACTS.596B |
0.352 |
|
| 2007 |
Nathan SD, Saggar R, Barnett S, Belperio JA, Ahmad S, Ross DJ, Shlobin OA, Saggar R, Libre E, Lynch JP, Zisman DA. ECHOCARDIOGRAPHY AS A PREDICTOR OF PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS Chest. 132: 428B. DOI: 10.1378/CHEST.132.4_MEETINGABSTRACTS.428B |
0.31 |
|
| 2006 |
Deb S, Yun J, Burton N, Omron E, Thurber J, Nathan SD. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest. 130: 214-7. PMID 16840404 DOI: 10.1378/CHEST.130.1.214 |
0.336 |
|
| 2006 |
Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 129: 746-52. PMID 16537877 DOI: 10.1378/CHEST.129.3.746 |
0.332 |
|
| 2005 |
Frenia D, Nathan SD, Ahmad S, Guerrero M, Distefano D, Massamiano P, Lefrak E, Burton N. Successful lung transplantation from a donor with a saddle pulmonary embolus. The Journal of Heart and Lung Transplantation : the Official Publication of the International Society For Heart Transplantation. 24: 1137-9. PMID 16102459 DOI: 10.1016/J.HEALUN.2004.06.027 |
0.323 |
|
| 2004 |
Burton NB, Browning RF, Lettieri CJ, Valentine VG, Ahmad S, Nathan SD. Outcomes of Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis Receiving Gamma-Interferon 1b Chest. 126: 889S. DOI: 10.1378/CHEST.126.4_MEETINGABSTRACTS.889S-A |
0.319 |
|
| 2003 |
Nathan SD, Barnett SD, Urban BA, Nowalk C, Moran BR, Burton N. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest. 123: 1758-63. PMID 12740298 DOI: 10.1378/CHEST.123.5.1758 |
0.318 |
|
| 2003 |
Nathan SD, Barnett SD, Ahmad S, Brown K, Burton NA. Influence of Baseline Forced Expiratory Volume on the Development of Bronchiolitis Obliterans Syndrome in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis Single Lung Transplant Recipient Chest. 124: 198S. DOI: 10.1378/CHEST.124.4_MEETINGABSTRACTS.198S |
0.331 |
|
| 2003 |
Barnett SD, Ahmad S, Tolleris CB, Hourigan S, Nathan SD. Comparison of Survival between Bilateral and Single Lung Transplants in Idiopathic Pulmonary Fibrosis Recipient Chest. 124: 100S. DOI: 10.1378/chest.124.2.771 |
0.315 |
|
| Show low-probability matches. |